Texas judge adds to J&J woes in Saffran case; ReGen, NMT can't file annual reports;

> A federal judge in Texas has added $111 million in pre-judgment interest to a $482 million verdict against Johnson & Johnson for allegedly infringing a patent held by a New Jersey radiologist with its coronary stent Cypher. Item

> Both ReGen Biologics and NMT Medical lack the funds to pay for their respective annual earnings filings with the SEC. Article | Story

> A study of roughly 500 individuals who helped craft treatment guidelines for heart conditions found that more than half reported financial conflicts of interest involving drug companies and medical technology firms. Report

> A new gel developed by researchers in New Zealand and Adelaide will aid healing and eliminate scarring for millions of people undergoing nasal surgery around the world. The gel, produced from shellfish and squid, is used as a wound dressing for the nose. Story

> Joslin Diabetes Center has named its board chairman John L. Brooks, III, as president and CEO. Brooks has been the acting CEO since the retirement of Cr. Kenneth Quickel, Jr., in October 2010. Brooks is a co-founder of Insulet, a Bedford, Mass.-based maker of insulin infusion devices. News

> Abiomed's stock is up 51 percent for the first quarter. Story

> Metro Mold & Design, a Rogers, MN-based plastics molding and precision manufacturer, plans to transfer 40 workers by late summer to a 100,000-square-foot building in Brooklyn Park. The $45 million company also is promising to create 40 more jobs at the new site in the near future. Metro Mold counts among its clients several of Minnesota's major medical device manufacturers. Article

> The University of Texas Health Science Center at San Antonio inked an agreement with cancer diagnostics company Biomoda on a research collaboration. Albuquerque, N.M.-based Biomoda is developing CyPath as a diagnostic test for lung cancer. Item

And Finally... Another Nevada doctor has reported himself to the board and began notifying his patients that he has reused single-use medical devices during prostate biopsy procedures, the Las Vegas Review-Journal reports. News

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.